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2Abstract.
Background. mRNA deadenylation (shortening of the poly (A) tail) is often triggered 
by specific sequence elements present within mRNA 3' untranslated regions and 
generally causes rapid degradation of the mRNA. In vertebrates, many of these 
deadenylation elements are called AU-Rich Elements (ARE). The EDEN (Embryo 
Deadenylation ElemeNt) sequence is a Xenopus "class III" ARE. The EDEN acts by 
binding a specific factor, EDEN-BP (EDEN-Binding Protein) that in turn stimulates 
deadenylation. 
Results. We showed here that EDEN-BP is able to oligomerize. A 27 amino acids 
region of EDEN-BP was identified as a key domain for oligomerization. A mutant of 
EDEN-BP deleted of this region was unable to oligomerize, and a peptide 
corresponding to this region competitively inhibited the oligomerization of full-length 
EDEN-BP. Impairing oligomerization by either of these two methods specifically 
abolished EDEN-dependent deadenylation. Furthermore, impairing oligomerization 
inhibited the binding of EDEN-BP to its target RNA, demonstrating a strong coupling 
between EDEN-BP oligomerization and RNA binding. 
Conclusions. These data showing that the oligomerization of EDEN-BP is required for 
binding of the protein on its target RNA and for EDEN-dependent deadenylation in 
Xenopus embryos will be important for the identification of cofactors required for the 
deadenylation process. 
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3Introduction.
 The post-transcriptional regulation of mRNAs in the cytoplasm is an important 
process implicated in controlling the dynamic changes in the expression of a number 
of regulatory proteins. Furthermore, in the early embryos of many, if not all, 
metazoans, gene transcription is essentially silent and the post-transcriptional 
controls exerted on the inherited maternal mRNAs are of paramount importance for 
the ensuing development. The post-transcriptional regulation affecting maternal 
mRNAs has been largely studied in Xenopus (Xenopus laevis) early embryos that are 
particularly suited to these studies due to their large size and availability. Studies in a 
number of laboratories have shown that the translation of maternal mRNAs is tightly 
correlated with the adenylation status; mRNAs that are polyadenylated are in general 
recruited into polysomes and translated whereas deadenylated mRNAs are released 
from polysomes (reviewed in Paillard and Osborne, 2003). In the large majority of 
cases in eukaryotes, deadenylation (shortening of the poly (A) tail) is the rate-limiting 
event of mRNA degradation. In Xenopus embryos, this is not the case as mRNA 
degradation does not immediately follow deadenylation. Although deadenylated 
mRNAs are not translated, they are stable until the blastula stage, several hours after 
fertilization (Audic et al., 1997; Voeltz and Steitz, 1998). Therefore, mRNA 
deadenylation and degradation, although causally coupled, are temporally separated. 
Targeting of a mRNA for deadenylation is generally achieved via specific cis 
sequence element(s) that reside within mRNA 3' untranslated regions (3'UTR). These 
cis elements bind specific proteins that in turn influence mRNA deadenylation. The 
rapid deadenylation of unstable mRNAs such as those encoding mammalian 
cytokines or proto-oncogenes is mediated by AU-rich elements (AREs) that have 
been divided into three classes, depending on the presence and the distribution of 
the core motif AUUUA (Chen and Shyu, 1995). A number of ARE-binding proteins 
have been characterized, and a role, either stimulatory or inhibitory, in mRNA 
deadenylation established for some of them (for a recent review see Barreau et al., 
2005).
We have shown previously that a sequence termed EDEN (Embryo 
Deadenylation ElemeNt), and an associated RNA-binding protein (EDEN-BP) are 
responsible for the deadenylation of a subclass of mRNAs after fertilization of 
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4Xenopus eggs (Paillard et al., 1998). Immunodepletion of EDEN-BP from egg 
extracts abolishes EDEN-dependent deadenylation activity (Paillard et al., 1998), that 
is restored by the addition of recombinant protein (Paillard et al., 2003). When EDEN-
BP was depleted in developing embryos by the injection of specific antibodies or 
morpholino antisense oligonucleotides, an important disruption of somite 
segmentation was observed (Gautier-Courteille et al., 2004). Interestingly, a reporter 
RNA containing human c-jun ARE, a "class III" (non-AUUUA containing) ARE (Chen 
and Shyu, 1995), is rapidly deadenylated after injection in Xenopus embryos. This 
deadenylation is also abrogated by immunoneutralizing EDEN-BP, demonstrating 
that it depends on active EDEN-BP (Paillard et al., 2002). This similarity between 
human c-jun ARE and Xenopus EDEN sequences led us to propose that EDEN 
sequences define a subgroup of class III AREs (Paillard et al., 2002). EDEN-BP is 
one member of the CELF (CUG-binding and Etr3 like factors) family of RNA-binding 
proteins (for a recent review, Barreau et al., 2006) and human CUG-BP1/CELF1 can 
act as a deadenylation factor in HeLa cell extracts (Moraes et al., 2006). 
 As for most ARE/ARE-binding proteins, the molecular mechanism linking 
EDEN-BP binding to a RNA and rapid deadenylation remains essentially unknown. A 
first step toward understanding this mechanism is to identify the partners of EDEN-
BP. Here, we have demonstrated using a biochemical assay that EDEN-BP can 
oligomerize, and we have mapped a domain required for this oligomerization. 
Moreover, using deletion mutants and a peptide derived from the interaction domain, 
we demonstrated the functional importance of EDEN-BP oligomerization for EDEN 
deadenylation and RNA binding. This is therefore an important step toward 
understanding the molecular composition of the protein complex that is targeted to 
mRNAs by the EDEN and is responsible for rapid deadenylation. 
RESULTS 
Identification of a 27 amino acid domain of EDEN-BP required for 
oligomerization
We have previously observed that EDEN-BP is able to interact with itself in a 
yeast two-hybrid assay (Bonnet-Corven et al., 2002). However, the yeast system can 
not be taken as a definitive proof that such interactions occur. Therefore, to more 
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5clearly demonstrate an EDEN-BP/EDEN-BP interaction, a "GST pull-down" assay 
was developed. Radiolabelled, untagged EDEN-BP was incubated with GSH beads 
previously loaded with GST protein, or a fusion of GST with EDEN-BP. The eluate 
was analyzed by electrophoresis and autoradiography (Figure 1A). A significant 
percentage of the loaded protein was detected in the eluate of the GST-EDEN-BP 
column (lane 3), as compared with the eluate from the GST column (lane 2). Only a 
weak signal was detected when the unrelated protein Xenopus Elongation Factor 1Į
(XEF1Į) was chromatographed on the GST-EDEN-BP column (lane 6), and this 
signal was not significantly above the background signal obtained after 
chromatography on the GST column (lane 5).
 To ensure that the binding of EDEN-BP to the GST EDEN-BP fusion protein 
could occur in the context of the embryo, Xenopus eggs were injected with a mRNA 
encoding a GST-EDEN-BP fusion protein and incubated to allow synthesis of this 
protein. Undiluted cytoplasmic extracts containing the GST EDEN-BP fusion protein 
were made from the injected eggs and these extracts were complemented with 35S
labelled EDEN-BP or Firefly luciferase in a minimal amount of rabbit reticulocyte 
lysate. After incubation with GSH beads, the retained proteins were eluted and 
analysed by electrophoresis and after transfer to a nitrocellulose membrane. The 35S
labelled proteins were revealed by autoradiography and quantified (Figure 1B, upper 
panel). To ensure that equivalent amounts of the fusion protein had been retained on 
the GSH beads the membrane was then probed with an anti GST antibody (Figure 
1B, lower panel). These analyses showed that the 35S labelled EDEN-BP was 
retained on the beads (lane 2) whereas the unrelated 35S labelled Firefly luciferase 
was not (lane 6). In these experiments, the 35S labelled EDEN-BP and the 
endogenous EDEN-BP can both bind to the GST-EDEN-BP, hence the amount of 
input radiolabelled protein retained on the beads is less than when only recombinant 
protein is used as in Figure 1A. Importantly, addition of RNase A to the extract before 
incubation with the beads did not significantly decrease the amount of labelled 
EDEN-BP retained by the fusion protein on the GSH beads (in Figure 2B, upper 
panel, compare lanes 2 and 4).
These data confirm the yeast two-hybrid data that EDEN-BP interacts with 
itself. Furthermore, they demonstrate that this interaction is not dependent on the 
presence of RNA. Finally, this interaction is observed both in the context of the 
embryo cytoplasm and in vitro using proteins expressed in bacteria. We will refer to 
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6the self association of EDEN-BP as oligomerization, as it can not be determined from 
these experiments if EDEN-BP forms a dimer or a higher oligomer.
 We next used the GST-pull-down assay to identify the domain of EDEN-BP 
that is required for oligomerization. In preliminary experiments, fragments of EDEN-
BP that were successively shortened from the COOH-terminal extremity were 
synthesised in reticulocyte lysates and tested for their capacity to be retained on 
GST-EDEN-BP beads. We observed that a fragment of EDEN-BP covering amino 
acids 1 to 238 (see Figure 2 for a schematic diagram of EDEN-BP) was efficiently 
retained on the GST-EDEN-BP, whereas this was not the case for the fragment 
covering amino acids 1 to 155 (data not shown). These preliminary results indicated 
that the 84 amino acids region of EDEN-BP between residues 155 and 238 is a key 
determinant in EDEN-BP oligomerization. This was tested by constructing a deletion 
mutant of EDEN-BP that was devoid of amino acids 155 to 238 (EDEN-BP ǻ155-
238). As indicated in the diagram in Figure 2, amino acid 155 borders the second 
RNA Recognition Motifs (RRM), therefore this deletion covers part of the linker region 
between RRMs 2 and 3. The ability of this deletion mutant to associate with EDEN-
BP was assayed in a GST-pull-down assay in parallel with the full length protein 
(Figure 2). As previously shown, full-length EDEN-BP was retained (lane 6). Relative 
to the amount of full length protein retained on the beads, about 3 times less of this 
mutant EDEN-BP was retained on the GST-EDEN-BP beads (lane 7). To further 
delimit the region of EDEN-BP required for oligomerization, a second mutant protein 
was made in which the central one third (amino acids 184 to 210) of this 84 amino 
acid region was deleted. When analysed in the GST-pull-down assay with full length 
GST EDEN-BP, the EDEN-BP ǻ184-210 mutant was significantly less well retained 
on the column (Figure 2, lane 8). As a control, the capacity of GST EDEN-BP to 
capture a 52kDa portion of an unrelated protein (Xenopus CAP-D2, previously 
referred to as pEg7 (Cubizolles et al., 1998)) was tested. Although some of this N-
terminal fragment of XCAP-D2 protein was retained, the amount was about 4 times 
less than that for the full length EDEN-BP and about half of that for the EDEN-BP 
ǻ184-210 mutant. These results identify a region of 27 amino acids, which is 
necessary for the oligomerization of EDEN-BP; they do not imply that this region is 
sufficient for oligomerization. Furthermore, we can not formally exclude that EDEN-
BP molecules do not interact via other regions of the protein. 
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does not support rapid deadenylation 
 We have previously shown that EDEN-BP provokes the rapid deadenylation of 
EDEN-containing RNAs (Paillard et al., 1998). To test if the oligomerization of EDEN-
BP is required for deadenylation we used cytoplasmic egg extracts that are proficient 
for EDEN-dependent deadenylation (Legagneux et al., 1995) and an EDEN-BP 
immunodepletion/rescue protocol. EDEN-dependent deadenylation is characterised 
by the appearance of completely deadenylated (A-) transcript containing an EDEN 
("EDEN", Gb-Eg2-410 (Legagneux et al., 1995)) upon incubation in these extracts 
(see Figure 3, lanes 1-3). Transcripts devoid of an EDEN or other regulatory 
sequence elements are also deadenylated in these extracts, albeit much less rapidly, 
by a "default" process (see the gradual shortening of the "Default" transcript (Gb-
Eg2-410A (Legagneux et al., 1995)). For the default transcript no completely 
deadenylated molecules are formed even after 3 hours of incubation (see Figure 3, 
lanes 1-3). We have previously shown (Paillard et al., 1998) that immunodepletion of 
EDEN-BP from egg extracts abolishes EDEN-dependent deadenylation and that the 
addition of recombinant, full-length EDEN-BP, can restore EDEN-dependent 
deadenylation (Paillard et al., 2003). Default deadenylation is not affected by these 
changes in EDEN-BP. Therefore to analyse the effect of EDEN-BP oligomerisation 
on EDEN-dependent deadenylation the above mentioned transcripts (radiolabelled 
and capped) were incubated in extracts depleted or not of EDEN-BP (Figure 3, lanes 
4–12 and 1-3 respectively). The EDEN-BP depleted extracts were complemented 
with wheat germ lysate that had been either left unprogrammed by a mRNA (lanes 4–
6) or programmed with mRNAs encoding full length EDEN-BP (lanes 7–9) or the 
EDEN-BP ǻ184-210 mutant (lanes 10-12). As expected the immunodepletion of 
EDEN-BP abrogated the EDEN-dependent deadenylation (lanes 4–6) and this 
activity was restored by the addition of full length EDEN-BP (lanes 7–9). In contrast, 
the EDEN-BP ǻ184-210 mutant was unable to restore EDEN-dependent 
deadenylation (lanes 10–12). Full-length and mutant EDEN-BP were produced in the 
presence of trace amounts of 35S-aminoacids, allowing a verification that similar 
concentrations of these two proteins were added (Figure 3, right panel). Hence, the 
27 amino acids deletion mutant that is unable to oligomerize (Figure 2) does not 
support EDEN-dependent deadenylation. 
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deadenylation 
The above data strongly suggest that the oligomerization of EDEN-BP is 
required for EDEN-dependent deadenylation. However, the incapacity of mutant 
EDEN-BP to support EDEN deadenylation could also be an indirect consequence of 
the deletion of the domain required for oligomerization, for instance if this deletion 
modified some structural aspects of EDEN-BP. To confirm that oligomerization is 
required for EDEN deadenylation, we designed another tool to inhibit EDEN-BP 
oligomerization, namely, a peptide corresponding to the sequence of the amino acids 
of EDEN-BP required for oligomerization that should compete with full-length EDEN-
BP, and thereby inhibit oligomerization by site occupation. 
A peptide corresponding to the region 183-210 of EDEN-BP was chemically 
synthesized. As a control, another peptide, containing the same amino acids as 
peptide 183-210 but in a different order ("scrambled" peptide) was also synthesized. 
The effects of these two peptides on oligomerization were tested in a GST-Pull-Down 
assay (Figure 4A). As above, a strong signal corresponding to EDEN-BP was 
detected in the eluate of the GST-EDEN-BP beads (0 peptide, lane 2). This signal 
was reduced about 3 fold when the incubation was performed in the presence of 100 
or 400 µM of peptide 183-210 (lanes 3 and 4). In contrast, the same concentration of 
the Scrambled peptide had no effect on the capacity of the GST-EDEN-BP beads to 
retain radiolabelled EDEN-BP (lanes 5 and 6).
We next tested the effects of the 183-210 and scrambled peptides on 
deadenylation in egg extracts. Various concentrations of the scrambled peptide were 
added to a deadenylation-proficient egg extract, and two test transcripts were 
incubated in these supplemented extracts (Figure 4B). Scrambled peptide 
concentrations up to 400 µM (upper panel) had no detectable effect on either EDEN-
dependent deadenylation, as measured with the "EDEN" transcript, or on default 
deadenylation ("Default" transcript). In the same experiment, 400 µM of peptide 183-
210 (lower panel, lanes 13-16) almost completely inhibited EDEN-deadenylation, but 
had no effect on the default deadenylation. 160 or even 64 µM of peptide 183-210 
also hampered EDEN-deadenylation though less efficiently and still had no effect on 
default deadenylation (lanes 5-12). Quantification of these data (Figure 4C, left 
panel), showed that the percentage of completely deadenylated EDEN-containing 
transcript increased with the time of incubation, but less and less rapidly as 
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deadenylated transcript accumulated is a direct indication of the deadenylation 
efficiency (right panel). Comparison of these efficiencies for the various samples 
confirmed that the Scrambled peptide had no effect on EDEN-dependent 
deadenylation, whereas this deadenylation was decreased by peptide 183-210 in a 
dose-dependent manner, reaching 10% of the control with 400µM of peptide. 
Therefore, peptide 183-210, but not a scrambled version of this peptide, specifically 
inhibits EDEN-dependent deadenylation.
Three supplementary controls for the specificity of the peptide 183-210 were 
made. First, we verified that the effect that was previously observed in cell-free 
extracts was the same in vivo. The capped, radiolabelled, EDEN-containing transcript 
was injected into Xenopus embryos, together with water (Figure 5 upper panel, lanes 
1-4), or 200 ng of peptide 183-210 (lanes 9-12). Assuming a homogenous distribution 
of the injected peptide inside the cell, this would correspond to a peptide 
concentration of about 300 µM. The adenylation behaviour of the reporter transcript 
was analyzed by denaturing electrophoresis and autoradiography of RNAs extracted 
at different times after injection (Figure 5, upper panel). As in extracts (Figure 4B), 
when injected with water, the reporter RNA was very rapidly shortened to the position 
of the completely deadenylated transcript (lanes 1-4), whereas this deadenylation 
was significantly reduced by the 183-210 peptide (lanes 9-12). Second, we verified 
that this inhibition of the EDEN-dependent deadenylation was not observed with any 
peptide derived from the sequence of EDEN-BP. A peptide of the same length as the 
183-210, and corresponding to the sequence of EDEN-BP immediately adjacent 
(155-182) was chemically synthesized. When injected into Xenopus embryos (200 
ng/embryo), this peptide had virtually no effect on the rapid deadenylation of the 
EDEN-containing transcript (Figure 5 upper panel, lanes 5-8). 
Third, we verified that the inhibitory effect of the peptide 183-210 on EDEN-
dependent deadenylation was observed with substrates other than the Eg2-derived 
EDEN-containing transcript used in previous figures. Accordingly, two additional 
transcripts were used, the synthetic globin ORF (Gb ORF, (Audic et al., 1997)) and 
this same mRNA containing the c-jun ARE in the 3'UTR (GbORFjun (Paillard et al., 
2002)). The GbORF mRNA is a substrate for default deadenylation whereas the 
GbORFjun mRNA is deadenylated by the EDEN-dependent process (Audic et al., 
1997; Paillard et al., 2002). As shown in Figure 5 (middle panel) the slow 
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deadenylation of the GbORF mRNA injected into embryos was not affected by the 
co-injection of 200 ng of the 183-210 peptide. In contrast the deadenylation of the 
GbORFjun transcript was strongly inhibited by the 183-210 peptide (Figure 5 lower 
panel, compare lanes 4-6 with 1-3). We have shown above that this peptide has no 
effect on the slow, default-type deadenylation (see Figure 4B). We also observed that 
it did not inhibit the AUUUA-dependent deadenylation, a rapid mechanism in 
Xenopus embryos that does not require active EDEN-BP (Paillard et al., 2002; Voeltz 
and Steitz, 1998) (data not shown). Hence, peptide 183-210 specifically inhibits the 
deadenylation of EDEN-containing transcripts in Xenopus embryos or extracts, but 
not other types of deadenylation. 
Oligomerization of EDEN-BP is required for RNA binding 
We previously observed that binding of EDEN-BP to the EDEN motif required 
sequence information proximal to amino acid 320 (Bonnet-Corven et al., 2002). This 
suggested to us that RNA binding may require EDEN-BP oligomerization. To test 
this, an Electrophoretic Mobility Shifts Assay (EMSA) was used. Increasing 
concentrations of purified recombinant, His-tagged EDEN-BP were incubated with 
radiolabelled s3'Eg5wt RNA. This RNA was chosen as an EMSA probe since it 
contains all the necessary sequence information to be a target of the EDEN-
dependent mechanism when injected in Xenopus embryos, but is reasonably short 
(120 nucleotides) (Paillard et al., 1998). Two radiolabelled complexes were detected 
(Figure 6A). As the reaction mix only contains purified recombinant EDEN-BP and 
s3'Eg5wt RNA, they probably correspond to increasing states of oligomerization of 
EDEN-BP on this target RNA. Based on three independent experiments, the 
concentration of EDEN-BP required to achieve 50% of bound s3'Eg5wt RNA is 15 +/-
5 nM. To verify the specificity of these complexes, the same experiment was 
reproduced using s3'Eg5C6 as an EMSA probe. This RNA contains a 6 nucleotides 
mutation (C6) within the EDEN sequence that is sufficient to strongly decrease 
EDEN-BP binding in UV-cross-linking or affinity chromatography assays (Paillard et 
al., 1998). The EMSA pattern obtained with this probe was very different, and a small 
amount of bound probe was only detected with the highest concentrations of EDEN-
BP tested (Figure 6B); the concentration of EDEN-BP required to achieve 50% of 
binding of this mutant probe is therefore far more than 200 nM. 
Biology of the Cell Immediate Publication. Published on 12 Jul 2006 as manuscript BC20060054
Copyright 2006 Portland Press Ltd.
The final Version of Record is available at www.biolcell.org
11
When an EMSA was made in the presence of 0.3 mM of peptide 183-210, 
binding to s3'Eg5wt RNA was strongly impaired (Figure 6C). Virtually no bound probe 
was detected even with the highest concentrations of EDEN-BP tested. Finally, the 
peptide "Scrambled" did not alter the EMSA pattern (Compare Figure 6D to 6A) nor 
the concentration of EDEN-BP required to achieve 50% binding of the probe (14 +/- 4 
nM, three independent experiments). Therefore, EDEN-BP requires oligomerization 
to bind the RNA substrate. 
DISCUSSION 
In this article, we demonstrated by a biochemical assay that EDEN-BP is able 
to interact with itself, and a 27 amino acids domain was mapped that is necessary for 
the interaction. A self-interaction of EDEN-BP was previously suggested based on 
yeast two-hybrid data (Bonnet-Corven et al., 2002). Two complementary tools were 
developed to analyze the requirement of this interaction for the functions of EDEN-
BP. First, a mutant of EDEN-BP devoid of the 28 amino acids domain did not 
oligomerize and did not support EDEN-dependent deadenylation in a 
depletion/rescue assay. Second, a peptide corresponding to this 28 amino acids 
domain impaired EDEN-BP oligomerization, and inhibited EDEN-dependent 
deadenylation both in vitro (extract) and in vivo (embryo). These results show that the 
oligomerization of EDEN-BP is required for rapid, EDEN-type deadenylation. 
The 28 amino acids EDEN-BP derived peptide that inhibited oligomerization 
and EDEN-dependent deadenylation also inhibited the binding of EDEN-BP to a 
substrate RNA, demonstrating that oligomerization is required for RNA binding. 
Examples of RNA-binding proteins that are able to oligomerize have been reported, 
and, in some cases, a reciprocal dependence of oligomerization and RNA binding 
was analysed. AUF1 was shown to be present as dimers in the absence of RNA. 
Upon RNA binding, AUF1 dimers are sequentially recruited to the host RNA, forming 
tetramers and higher polymers of dimers (Wilson et al., 1999). U1A is able to 
homodimerize even in mutants that have lost their capacity to interact with RNA; 
however, in the wild-type protein, homodimerization permits cooperative binding 
(Klein Gunnewiek et al., 2000). A mutant FMR1 (FMR1 I304N) that is unable to 
oligomerize can still interact with RNA (Laggerbauer et al., 2001). In these three 
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examples, RNA binding and oligomerization could be uncoupled, though 
oligomerization could reinforce binding. In contrast, it was shown by mutating key 
residues involved in homodimerization (as predicted from structural data) that yeast 
She2p dimerization is required for RNA binding (Niessing et al., 2004). This last 
situation is evocative of the strong relationship between RNA-binding and 
oligomerization that we describe here for EDEN-BP. 
The Drosophila protein Bruno is closely related to Xenopus EDEN-BP and 
acts as a translational repressor in oocytes (Castagnetti et al., 2000; Lie and 
Macdonald, 1999). Recently, Chekulaeva et al. (2006) showed that in Drosophila 
oocytes the binding of Bruno to oskar mRNA caused a oligomerisation of the mRNA 
in a silencing particle. This particle contains Bruno, Cup an eIF4E binding protein and 
Me31B that is a homolog of the yeast P-body component and translational repressor 
Dhh1P. To our knowledge it has not been determined whether Bruno alone can 
oligomerize but our data suggests that this may be the case and that the 
oligomerisation of oskar mRNA is driven by interactions between Bruno monomers. 
EDEN-BP is one member of the CELF/Bruno like family of RNA-BPs. 
Alignment of the 184 - 210 region of EDEN-BP with the corresponding region of the 
other CELF proteins (Figure 7) showed that this region is highly conserved between 
the CELF1 (EDEN-BP and CUG-BP1) and CELF2 (ETR-3 and CUG-BP2) proteins. 
These two proteins also exhibit the highest degree of overall similarity (see Barreau 
et al, 2006). The conservation of this region is less for CELF 3, 4 and 5 and the least 
for CELF 6. However, it should be noted that a certain number of the amino acid 
changes are conservative changes (eg K for R at positions 191, 193 and 196; E for D 
at position 192). This observation suggests that most if not all of the different CELF 
proteins are also able to oligomerise and that they could form homo- or hetero-
oligomers depending on the presence or absence of the different CELF proteins in 
the same cell. This potential flexibility in the RNA binding partner of a CELF protein 
may be at the base of the large variety of functions described for these proteins (see 
Barreau et al., 2006). 
Several  consequences can be envisaged to result from the oligomerisation of 
an RNA-BP. First, the binding site of the oligomerized proteins may not match a strict 
linear "consensus". The sequence could be either direct or an inverted repeat and 
each individual "motif" could be separated by a variable spacer that could be looped 
out when the RNA /protein complex formed. Second, the oligomerization could create 
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new surfaces with which partners can interact and these surfaces could evolve with 
the degree of oligomerisation. In this context it is interesting that Chekulaeva et al. 
(2006) observed that the protein Cup was present in the heavy but not the light RNP 
complexes. This would mean that oligomerization of a RNA-BP on a RNA gives 
added value to binding specificity. Only those mRNAs that can bind two or more 
molecules of the RNA-binding protein will be a site for complex formation that is 
required to fulfil the specific function. 
EXPERIMENTAL PROCEDURES 
Recombinant protein production
EDEN-BP open reading frame was PCR amplified and cloned into the pTRC-
His (Invitrogen) and pGEX2T (Amersham Pharmacia) plasmids to yield pTRC-His-
EDEN-BP and pGEX2T-EDEN-BP. His-EDEN-BP and GST-EDEN-BP were 
produced from these respective plasmids in TOP10 bacteria by overnight induction at 
25°C with 5 mM Isopropyl-Thiogalactoside (IPTG). They were purified on Ni-NTA 
agarose (Qiagen) or GST-Sepharose 4B (Amersham Pharmacia) columns following 
the instructions of the manufacturers. 
To produce GST-EDEN-BP in vivo unfertilised Xenopus eggs were injected 
with 5 ng of in vitro synthesised GST-EDEN-BP mRNA and incubated for 4h at 20°C 
before making deadenylation proficient (Legagneux et al., 1995). 
Radiolabelled EDEN-BP was produced by in vitro transcription and translation 
(ProteinScript II, Ambion) in the presence of 35S-aminoacids using the pT7TS-EDEN-
BP plasmid (Paillard et al., 2002) as a matrix. Radiolabelled COOH-shortened 
fragments of EDEN-BP were produced similarly, but the transcription matrices used 
were PCR products containing the fragments of EDEN-BP previously described 
(Bonnet-Corven et al., 2002) amplified with the following primers #82, 
GCGTAATACGACTCACTATAGGGCTATGGCTGGGATCCGGTACCG (contains a 
promoter for T7 RNA polymerase, bold), and #81, GTGACACTATAGAACCAGATCG. 
EDEN-BP ǻ155-238 was produced as follows. First, the fragment corresponding to 
the amino acids 1 to 154 was PCR amplified with the following primers: #608, 
GAAGATCTGCCATGAATGGCACAATGGACC (contains a BglII site, italicized, and 
EDEN-BP translation initiation codon, bold) and #549, 
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CCACTTAGGGAGTTGAGGTTCGTAACGAATGCACATCCTC. The fragment 
corresponding to the amino acids 239 to 489 was PCR amplified with the following 
primers: #550, GAGGATGTGCATTCGTTACGAACCTCAACTCCCTAAGTGG and 
#609, GCTCTAGATCAGTAGGGTTTGCTGTCATTC (contains a XbaI site, italicized 
and EDEN-BP translation termination codon, bold). Primers #549 and #550 are 
complementary. Second, the two PCR products were mixed and used for a second 
round of PCR with primers #608 and #609. The resulting amplimere was digested 
with BglII and XbaI and cloned in the BglII and SpeI sites of the pT7TS vector 
(Cleaver et al., 1996). EDEN-BP ǻ184-210 was similarly produced, except that the 
first rounds of PCR used primers #543, 
CCAGTCAGGTTACCCCACATTGAGGCCACTATTGGTGAGGAACAGCCC (instead 
of #549), and #544, 
GGGCTGTTCCTCACCAATAGTGGCCTCAATGTGGGGTAACCTGACTGG (instead 
of #550). These internal mutant deletions were produced either as radiolabelled 
proteins with the ProteinScriptII kit as above or, for rescue experiments, by in vitro 
transcription (Message Machine, Ambion) and translation in nuclease-treated Wheat 
Germ Extract (Promega) in the presence of trace amounts of 35S-aminoacids. The 
control radiolabelled Xenopus Elongation Factor 1Į was produced from the pTRI-
XEF plasmid provided by Ambion. The portion of Xenopus CAP-D2 (XCAPD2 
previously named pEg7) (Cubizolles et al., 1998) cDNA corresponding to the 465 N-
terminal amino acids was cloned into the pT7TS vector. The corresponding 
radiolabelled protein (52.2 kDa) was produced with ProteinScript kit as above. 
Peptides
Peptides used were synthesized and HPLC-purified by the Service 
Protéomique de l'Est du Quebec, Quebec, Canada. They were dissolved in water at 
10 mg/ml (about 3 mM), aliquoted and stored at -70°C. Their sequences are: 
155-182: FTTRSMAQMAIKSMHQAQTMEGCSSPIV 
183-210: VKFADTQKDKEQKRMTQQLQQQMQQLNA 
Scrambled of 183-210: ATQLQEDQVQANQQQMQKRMKKDKFTQL. 
Biochemical methods
For each GST-pull down assay, 2 µg of proteins (GST or GST-EDEN-BP) 
were incubated with 40 µl of GSH-Sepharose beads (Amersham Pharmacia), rinsed 
Biology of the Cell Immediate Publication. Published on 12 Jul 2006 as manuscript BC20060054
Copyright 2006 Portland Press Ltd.
The final Version of Record is available at www.biolcell.org
15
and equilibrated in H buffer (Tris 50 mM pH 7.8; NaCl 50 mM; EDTA 1mM; DTT 1 
mM; NP-40 1% supplemented with 10 µg/ml (each) of leupeptin, pepstatin and 
chymostatin). The protein beads were then incubated (2h, 4°C) with 5 µl of 
radiolabelled protein diluted in 5 µl of H buffer and containing the appropriate 
peptides when required. Beads were rinsed 3 times by 1 ml of H buffer and eluted by 
boiling in SDS buffer. The eluted proteins were separated by denaturing 
electrophoresis and transferred to a nitrocellulose membrane. The 35S labelled 
EDEN-BP was revealed by autoradiography using phosphoimager screen. The 
amount of bound protein was quantified using a Phosphoimager (STORM 840, 
Molecular Dynamics). Quantifications were made using the ImageQuant software 
(Version 5.4, Molecular Dynamics). 
For GST-pull down assays using in vivo translated GST-EDEN-BP, 25 µl of 
extract from embryos injected with GST-EDEN-BP mRNA were mixed with 5µl of 
Rabbit reticulocyte lysate previously programmed with mRNA encoding either EDEN-
BP or Firefly Luciferase (Promega) and supplemented with 35S-aminoacids. The 
resulting solution was incubated for 1h at 20°C to facilitate integration of the 35S
labelled EDEN-BP into pre-formed complexes and then processed as above. Where 
indicated RNase A (1ng/µl) was added to the solution of GST-EDEN-BP and 35S
labelled EDEN-BP that was then incubated (1h, 20°C) before addition of the GSH 
beads.
 For Electrophoretic Mobility Shift Assays (EMSA), serial dilutions of His-EDEN-
BP were made in the following buffer: HEPES 70mM (pH=7.9); KCl 150 mM; EDTA 
0.08 mM; MgCl2 2 mM; DTT 0.2 mM; Glycerol 8%; Yeast tRNA 2µg/µl; Heparin 6.6 
µg/µl; BSA 6.6 µg/µl; IGEPAL-CA30 0.06%, and peptide when required. 
Radiolabelled probes were made by in vitro transcription with Į32P-UTP and the 
Promega Riboprobe products using BamH1-linearized s3'Eg5wt and s3'Eg5C6 
plasmids (Paillard et al., 1998). 3 nM of heat-denatured radiolabelled transcript were 
added to the diluted proteins and incubated for 1h on ice. Complexes were separated 
by electrophoresis on 5% polyacrylamide gel in 0.5X TBE and 5% glycerol. The dried 
gels were submitted to Phosphoimager (STORM 840, Molecular Dynamics) analysis. 
Quantifications were made using the ImageQuant software (Version 5.4, Molecular 
Dynamics).
Deadenylation analyses
Biology of the Cell Immediate Publication. Published on 12 Jul 2006 as manuscript BC20060054
Copyright 2006 Portland Press Ltd.
The final Version of Record is available at www.biolcell.org
16
For deadenylation analyses, capped, polyadenylated, uniformly radiolabelled GbEg2-
410, GbEg2-410A, GbORF and GbORFjun transcripts were obtained by in vitro 
transcription in the presence of Į32P-UTP using the Promega Riboprobe products 
and the corresponding plasmids (Audic et al., 1997; Legagneux et al., 1995; Paillard 
et al., 2002) previously linearized with EcoRV. These transcripts were injected, alone 
or with peptides, into two-cell embryos. Alternatively, RNAs were incubated in 5 µl of 
deadenylation-proficient activated egg extracts (Legagneux et al., 1995). In some 
experiments, these extracts were mock depleted or immunodepleted of EDEN-BP as 
previously described (Paillard et al., 1998). Complementation with full-length or 
mutant EDEN-BP was made by mixing one volume of depleted extract with one 
volume of programmed wheat germ extract (Paillard et al., 2003). At the indicated 
times, pools of 5 embryos, or 5 µl of extract, were crushed in Tri-reagent 
(Euromedex), and RNAs were extracted following the instructions of the 
manufacturer. They were resolved on 4% polyacrylamide-urea gels before 
phosphoimager analysis (STORM 840, ImageQuant software). Quantifications were 
made using the ImageQuant software (Version 5.4, Molecular Dynamics). 
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FIGURES LEGENDS 
Fig. 1 EDEN-BP oligomerizes in vitro and in vivo. 
A, 5 µl of Rabbit reticulocyte lysate programmed to synthesize radiolabelled Xenopus 
EDEN-BP, MW 51.8 kDa (lane 2, 3) or Elongation Factor 1Į XEF1Į, MW 50.2 kDa 
(lanes 5, 6) were mixed with GSH-Sepharose beads that had been previously 
incubated with bacterially produced GST (lanes 2, 5) or GST-EDEN-BP (G-E, lanes 
3, 6). After incubation (90 min) and then extensive washing, the bound proteins were 
eluted by boiling in SDS buffer, and separated by denaturing electrophoresis. The 
radiolabelled proteins were revealed and quantified using a phosphoimager and 
ImageQuant software. Input corresponding to 1 µl of reticulocyte lysate expressing 
EDEN-BP (lane 1) or XEF1Į (lane 4) were loaded on the gel as input controls. The 
percentages of input protein retained on the beads are indicated below the lanes. B,
Upper panel, 25 µl of Xenopus egg cytosol extract made from eggs previously 
injected with GST-EDEN-BP mRNA was mixed with 5 µl of either EDEN-BP (lanes 2 
and 4) or Firefly Luciferase (lane 6) produced in reticulocyte lysates supplemented 
with 35S labelled amino acids and then incubated for 60 min. In lane 4, RNase A was 
added to the protein solution and the incubation continued for another 60 min. The 
samples were then processed and separated as in A. After electrophoresis the 
proteins were transferred to nitrocellulose membrane and the radiolabelled proteins 
were revealed and quantified using a phosphoimager and ImageQuant software. 
Inputs correspond to 3 µl of the mixed protein solution. The percentages of input 
protein retained on the beads are indicated below the lanes. Lower panel, After 
exposure to phosphoimager screens the membrane was probed with anti-GST 
antibodies that were revealed with alkaline phosphatase coupled to the secondary 
antibody and ECF using a Storm 840. 
Fig. 2 Mapping of the domain of oligomerization of EDEN-BP. 
Overall structure of EDEN-BP is shown at the top. The positions of the three RNA 
Recognition Motifs (RRM) are indicated. GST pull down assays were performed as in 
Figure 1A. 5 µl of reticulocyte lysate programmed to synthesize full-length (1-489, 
lane 6), the indicated mutants of EDEN-BP (lanes 7 and 8) or a portion of the 
unrelated XCAP-D2 protein (lane 5)  were mixed with GSH-Sepharose beads 
previously incubated with GST-EDEN-BP. 1 µl of reticulocyte lysate expressing the 
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same fragments of EDEN-BP were loaded on the gel as input controls (Input, lanes 1 
- 4). For the different recombinant proteins proportions of the input proteins retained 
on the beads are indicated below the lanes. 
Fig. 3 A domain of EDEN-BP required for oligomerisation is required for EDEN-
dependent deadenylation. 
Left panel. A deadenylation proficient egg extract was either untreated (lanes 1-3), 
or immunodepleted of EDEN-BP (lanes 4-12) and then supplemented with 
unprogrammed Wheat Germ extract (lanes 4-6) or Wheat Germ extract programmed 
to synthesize full length EDEN-BP (lanes 7-9) or EDEN-BP harbouring an internal 
deletion of the amino acids 184 to 210 (lanes 10-12). Capped, polyadenylated, 
radiolabelled Gb-Eg2-410 (EDEN) and Gb-Eg2-410A (Default) transcripts 
(Legagneux et al., 1995) were incubated in these extracts for the indicated times. 
RNAs were extracted and the adenylation behaviours of the transcripts were 
analyzed by denaturing electrophoresis. The radiolabelled RNAs were revealed and 
quantified using a phosphoimager and ImageQuant software. The positions of the 
polyadenylated (A+) and deadenylated (A-) RNAs are indicated on the left. 
Right panel. Autoradiogram of the radiolabelled full length (lane 2) and ǻ184-210
(lane 2) EDEN-BPs after separation from the unincorporated 35S-labelled amino acid 
by SDS-PAGE. 
Fig. 4. Peptide 183-210 inhibits EDEN-BP oligomerization and EDEN-dependent 
deadenylation.
A, 5 µl of reticulocyte lysate programmed to synthesize radiolabelled EDEN-BP were 
mixed with GSH-Sepharose beads previously incubated with GST-EDEN-BP (lanes 
2-6), in the presence of the indicated concentration of peptide 183-210 (lanes 3 and 
4) or Scrambled (Scrambled, lanes 5 and 6). Bound proteins were analyzed as 
described in the legend to Figure 1A. Lane 1 is an input control corresponding to 1 µl 
of reticulocyte lysate. The amount of EDEN-BP retained on the beads in the 
presence of the peptides, relative to that retained in the absence of peptides (lane 2) 
is indicated below the lanes. B, Capped, radiolabelled Gb-Eg2-410 (EDEN) and Gb-
Eg2-410A (Default) transcripts were incubated in Xenopus activated eggs extracts, 
together with the indicated concentrations of peptide 183-210 (lower panel) or 
scrambled (upper panel). RNAs were extracted at the indicated times, and their 
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adenylation behaviour was analyzed as described in the legend to Figure 3. C,
Quantification of the data shown in B. The left panel shows the percentage of the 
completely deadenylated form of the EDEN-containing transcript during the time of 
experiment. No peptide, black line, Scrambled peptide; 64 µM purple squares, 160 
µM blue disc, 400 µM red triangle; 183-210 peptide;  64 µM open purple square, 160 
µM open blue triangle, 400 µM red circle. Right panel, deadenylation efficiencies 
were estimated from the slopes of these lines, normalized to 100% for the control (no 
peptide) experiment, and are shown for the indicated concentrations of peptide 183-
210 (grey) or scrambled (black). 
Fig. 5. Specificity of the inhibitory activity of peptide 183-210.  
Upper panel, A capped, radiolabelled Gb-Eg2-410 (EDEN) transcript was injected 
into Xenopus embryos, together with water (lanes 1-4), or 200 ng of the indicated 
peptides (lanes 5-12). RNAs were extracted at the times indicated above each lane. 
The adenylation behaviour of the injected transcript was analyzed by denaturing 
electrophoresis and autoradiography as described in the legend to Figure 3. The 
positions of the polyadenylated (A+) and deadenylated (A-) RNA are indicated on the 
left.
Middle panel, A capped, radiolabelled GbORF transcript was injected into Xenopus 
embryos, together with water (lanes 1-5), or 200 ng of peptides 183-210 (lanes 6-10). 
RNAs were extracted at the times indicated above each lane and analyzed as above. 
Lower panel, A capped, radiolabelled GbORFjun transcript was injected into Xenopus 
embryos, together with water (lanes 1-3), or 200 ng of peptides 183-210 (lanes 4-6). 
RNAs were extracted at the times indicated above each lane and analyzed as above. 
Fig. 6. Peptide 183-210 inhibits EDEN-BP binding to an EDEN. 
3 nM of radiolabelled s3'Eg5wt (A, C, D) or s3'Eg5C6 (B) RNA was incubated with 
increasing concentrations of recombinant EDEN-BP (lane 1, 0; lane 2, 0.7 nM; lane 
3, 3 nM; lane 4, 12 nM; lane 5, 50 nM; lane 6, 200 nM). In C and D, incubations were 
performed in the presence of 0.3 mM of peptide 183-210 and Scrambled 
respectively. RNA-protein complexes were resolved by native electrophoresis and 
the radiolabelled RNAs were revealed and quantified using a phosphoimager and 
ImageQuant software. The positions of the free and bound probes are indicated. 
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Fig. 7. Alignment of amino acids 184 to 210 of EDEN-BP with the corresponding 
regions of other CELF proteins. 
Xenopus laevis EDEN-BP and human CUG-BP1 (hsCUG-BP1) are orthologous 
CELF1 proteins. Xenopus laevis Etr-3 (Xl Etr-3) and human CUG-BP2 (hsCUG-BP2) 
are the corresponding CELF2 proteins. The human sequences for the other CELF 
proteins are shown. (*) indicates a conserved amino acids; (:) indicates a 
conservative replacement. Amino acids identical to the Xenopus EDEN-BP sequence 
are on a grey background. 
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Cosson et al BoC Figure 7 
Xl EDEN-BP   VKFADTQKDKEQKRMTQQLQQQMQQLNA 
Xl ETR-3     VKFADTQKDKEQRRLQQQLAQQMQQLNT 
hs CUG-BP1   VKFADTQKDKEQKRMAQQLQQQMQQISA 
hs CUG-BP2   VKFADTQKDKEQRRLQQQLAQQMQQLNT 
hs CELF3     VKFADTEKERGLRRM QQVATQLGMFSP 
hs CELF4     VKFADTDKERTMRRM QQMAGQMGMFNP 
hs CELF5     VKFADTDKERTLRRM QQMVGQLGILTP 
hs CELF6     VKLADTDRERALRRM QQMAGHLGAFHP 
             ** *** :::  ::  **
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